Search results: Sage Journals

Open accessResearch articleFirst published 2025

Switch from fingolimod to ozanimod for safety or intolerance reasons

Elisabetta Signoriello, Giuseppe Romano, Matteo Foschi [...]

Therapeutic Advances in Neurological Disorders

Restricted accessReview articleFirst published May, 2022

Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis

David Choi, Alyssa P. Stewart, Shubha Bhat

Annals of Pharmacotherapy

Open accessResearch articleFirst published November, 2025

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial

Krzysztof W Selmaj, Lawrence Steinman, Giancarlo Comi [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published 2024

Comparative effectiveness and safety of ozanimod versus other oral DMTs in relapsing-remitting multiple sclerosis: a synthesis of matching-adjusted indirect comparisons

Damemarie Paul, Elyse Swallow, Oscar Patterson-Lomba [...]

Therapeutic Advances in Neurological Disorders

Open accessResearch articleFirst published August, 2019

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study

Jeffrey A Cohen, Giancarlo Comi, Douglas L Arnold [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published October, 2022

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial

Bruce AC Cree, Krzysztof W Selmaj, Lawrence Steinman [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published February, 2024

Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial

Robert T Naismith, Jeffrey A Cohen, Amit Bar-Or [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published September, 2025

Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials

Jeffrey A Cohen, Douglas L Arnold, John DeLuca [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published 2024

Appropriateness of small molecule agents for patients with IBD of childbearing age – a RAND/UCLA appropriateness panel

Christian Selinger, Robyn Laube, Jimmy K. Limdi [...]

Therapeutic Advances in Gastroenterology

Free accessReview articleFirst published October, 2017

Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges

Marcel Vetter, Markus F. Neurath

Therapeutic Advances in Gastroenterology

Open accessResearch articleFirst published 2025

Switch from fingolimod to ozanimod for safety or intolerance reasons

Elisabetta Signoriello, Giuseppe Romano, Matteo Foschi [...]

Therapeutic Advances in Neurological Disorders

Restricted accessReview articleFirst published May, 2022

Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis

David Choi, Alyssa P. Stewart, Shubha Bhat

Annals of Pharmacotherapy

Open accessResearch articleFirst published November, 2025

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial

Krzysztof W Selmaj, Lawrence Steinman, Giancarlo Comi [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published 2024

Comparative effectiveness and safety of ozanimod versus other oral DMTs in relapsing-remitting multiple sclerosis: a synthesis of matching-adjusted indirect comparisons

Damemarie Paul, Elyse Swallow, Oscar Patterson-Lomba [...]

Therapeutic Advances in Neurological Disorders

Open accessResearch articleFirst published August, 2019

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study

Jeffrey A Cohen, Giancarlo Comi, Douglas L Arnold [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published October, 2022

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial

Bruce AC Cree, Krzysztof W Selmaj, Lawrence Steinman [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published February, 2024

Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial

Robert T Naismith, Jeffrey A Cohen, Amit Bar-Or [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published September, 2025

Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials

Jeffrey A Cohen, Douglas L Arnold, John DeLuca [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published 2024

Appropriateness of small molecule agents for patients with IBD of childbearing age – a RAND/UCLA appropriateness panel

Christian Selinger, Robyn Laube, Jimmy K. Limdi [...]

Therapeutic Advances in Gastroenterology

Free accessReview articleFirst published October, 2017

Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges

Marcel Vetter, Markus F. Neurath

Therapeutic Advances in Gastroenterology